Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis.
Antimicrob Agents Chemother
; 50(10): 3499-500, 2006 Oct.
Article
em En
| MEDLINE
| ID: mdl-17005843
ABSTRACT
Two cohorts of four subjects requiring hemodialysis received tefibazumab (10 or 20 mg/kg). The mean elimination half-life was between 17 and 18 days, the average volume of distribution was 7.3 liters, and the average clearance was 12 ml/h for both dose groups. At a dose of 20 mg/kg of body weight, plasma levels were 88 microg/ml at 21 days.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Diálise Renal
/
Adesinas Bacterianas
/
Falência Renal Crônica
/
Anticorpos Monoclonais
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Antimicrob Agents Chemother
Ano de publicação:
2006
Tipo de documento:
Article
País de afiliação:
Estados Unidos